GlassScriptPhysician profile
Arun Koshy
NPI 1710907936
$5,464.30
in general payments reported to CMS, 2019-2025
26 companies · $467 in 2025
The $467 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $526 · 2021: $1,848 · 2022: $757 · 2023: $922 · 2024: $173 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,506.09 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,348.40 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $604.19 | 2019-2023 | Ofev |
| Janssen Pharmaceuticals, INC | $331.05 | 2021-2022 | |
| Grifols USA, LLC | $279.71 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $231.24 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $148.39 | 2020-2023 | Libtayo |
| Exelixis INC. | $125.53 | 2021 | |
| Myovant Sciences INC. | $115.40 | 2021 | |
| Daiichi Sankyo INC. | $100.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $94.84 | 2022 | |
| Kite Pharma, INC. | $85.26 | 2021 | |
| Abbvie INC. | $77.74 | 2023 | |
| Merck Sharp & Dohme LLC | $73.48 | 2019-2020 | |
| Philips North America LLC | $67.48 | 2020-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $45.10 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $40.08 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $37.70 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $31.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.94 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $20.80 | 2019 | |
| Shire North American Group INC | $18.56 | 2019 | |
| Amgen INC. | $17.00 | 2021 | |
| Electromed, INC. | $14.68 | 2022 | |
| Mylan Specialty L.P. | $13.27 | 2021 | |
| Genentech USA, INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Koshy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.